Who are recombinant birch pollen allergen's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): tree 12 SQ-Bet, AIT Tablet, Staloral TM, House dust mite Novo Helisen Depot, PURETHAL Grasses, 20.000 AUM/ml, sublingual immunotherapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/recombinant-birch-pollen-allergen.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

recombinant birch pollen allergen — Competitive Intelligence Brief

recombinant birch pollen allergen (recombinant birch pollen allergen) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Allergen immunotherapy. Area: Immunology / Allergy.

phase 3 Allergen immunotherapy Birch pollen allergens (Bet v 1 and related epitopes) Immunology / Allergy Biologic Live · refreshed every 30 min

Target snapshot

recombinant birch pollen allergen (recombinant birch pollen allergen) — Allergopharma GmbH & Co. KG. Recombinant birch pollen allergen is used in allergen immunotherapy to desensitize the immune system to birch pollen by inducing tolerance through repeated controlled exposure to the allergen.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
recombinant birch pollen allergen TARGET	recombinant birch pollen allergen	Allergopharma GmbH & Co. KG	phase 3	Allergen immunotherapy	Birch pollen allergens (Bet v 1 and related epitopes)
tree 12 SQ-Bet	tree 12 SQ-Bet	Clinique Spécialisée en Allergies de la Capitale	marketed	Allergen immunotherapy (sublingual tablet)	Tree pollen allergens (IgE cross-linking epitopes)
AIT Tablet	AIT Tablet	ALK-Abelló A/S	marketed	Allergen immunotherapy
Staloral TM	Staloral TM	National Taiwan University Hospital	marketed	Allergen immunotherapy
House dust mite Novo Helisen Depot	House dust mite Novo Helisen Depot	Allergopharma GmbH & Co. KG	marketed	Allergen immunotherapy
PURETHAL Grasses, 20.000 AUM/ml	PURETHAL Grasses, 20.000 AUM/ml	HAL Allergy	marketed	Allergen immunotherapy extract	Grass pollen allergens (IgE and T-cell epitopes)
sublingual immunotherapy	sublingual immunotherapy	University of Genova	marketed	Allergen immunotherapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Allergen immunotherapy class)

Allergopharma GmbH & Co. KG · 8 drugs in this class
HAL Allergy · 2 drugs in this class
Medical University of Silesia · 2 drugs in this class
ALK-Abelló A/S · 2 drugs in this class
Laboratorios Leti, S.L. · 1 drug in this class
National Taiwan University Hospital · 1 drug in this class
Royal Sussex County Hospital · 1 drug in this class
The University of Texas Medical Branch, Galveston · 1 drug in this class
University of Genova · 1 drug in this class
Anergis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). recombinant birch pollen allergen — Competitive Intelligence Brief. https://druglandscape.com/ci/recombinant-birch-pollen-allergen. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab